Illumina sees 2025 EPS of $4.50
Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue from China, after the country banned the importation of its DN | Illumina also lowered its annual financial forecast,
Today, Benzinga's options scanner identified 8 options transactions for Illumina. This is an unusual occurrence. The ...
The company has been under growing scrutiny from Beijing, after two of its Chinese rivals, MGI and BGI, were listed in a U.S.
Illumina has been barred from exporting its DNA sequencers to China, which closed | Illumina has been barred from exporting ...
The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson ...
Brown Advisors, an investment management company, released its “Brown Advisors Global Leaders Strategy” fourth quarter 2024 ...
Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs ...
Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, ...
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...
CEO of Illumina. "We are confident in the largeglobal marketopportunity for our solutions, the strength of our business, and our strategy to continue to lead innovation in genomics and multiomics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback